drugset / Trial / NCT02294292

Therapeutic Approach to Diastolic Dysfunction in Chronic Liver Disease Patients and Its Impact on Morbidity and Mortality

NCT02294292

RandomizedParallel-groupSingle-blindTreatment

Summary

Cirrhotic cardiomyopathy is defined as a chronic cardiac dysfunction in patients with cirrhosis. It is suspected that this specific cardiac dysfunction contributes to the onset of complications in liver disease. The purpose of this prospective, randomized controlled trial is to determine whether carvedilol can revert cardiac dysfunction i.e. left ventricular diastolic dysfunction secondary to cirrhosis, and prevent complications (renal dysfunction, worsening cardiac function, and mortality).

Timeline

Start
2014-07-01
Primary completion
2016-08-31
Completion
2016-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Carvedilol Other / unclassified
Subject Ivabradine Small molecule 15 mg